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A b s t r a c t
Introduction: Long lesions contribute to a significant number of percutaneous coronary interventions.
Aim: To assess the efficacy and safety of a novel long-tapered drug-eluting stent (DES) at a 12-month follow-up (FU) in patients 
with long coronary atherosclerotic lesions
Material and methods: A prospective clinical cohort study was conducted in 32 patients who underwent percutaneous coronary 
intervention using a BioMime Morph tapered stent (Meril Life Sciences, India). The patients were followed for 3, 6, and 12 months. 
The safety endpoints were death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization 
(TVR), and MACE and/or major bleeding.
Results: Mean lesion length was 48 mm (range: 35–70 mm) measured via quantitative coronary analysis (QCA). In most cases, 
the target lesion was located in the LAD (68.75%). A GuideLiner catheter (Vascular Solutions Inc., MN, USA) was used in 12.5% of 
procedures; buddy-wire technique in 9.4% of cases. Bifurcation lesions were treated in 40.6% of cases. Additional stent implantation 
was needed in 56% of the procedures (25% of cases due to proximal or distal dissection, or due to insufficient stent length in 31% 
of cases). On 12-month FU we observed 1 TLR (3.1%), 1 TVR (3.1%), and 1 non-cardiovascular death.
Conclusions: The long sirolimus-eluting stent with tapered structure was characterized by good deliverability in long coronary 
lesions, although in some cases “buddy wire” or extension microcatheter use was necessary. Follow-up at 3, 6, and 12 months 
showed no significant major adverse cardiovascular events related to the device.
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S u m m a r y
The long sirolimus-eluting stent with tapered structure was characterized by good deliverability in long coronary lesions, 
although in some cases “buddy wire” or extension microcatheter use was necessary. Previous lesion preparation even with 
non-compliant balloon is important for successful stent introduction. Operator experience plays an important role. Follow-up 
at 3, 6, and 12 months showed no significant major adverse cardiovascular events related to the device.
Introduction
Atherosclerosis is a progressive inflammatory disease 
and among the aging population becomes a challenge for 
interventional cardiologists [1–3]. Percutaneous treatment 
is recommended in most patients with significant coro-
nary artery disease (CAD) [4]. Long lesions contribute to 
a significant number of percutaneous coronary interven-
tions (PCI), which requires the use of multiple overlapping 
stents, mostly in the context of insufficient stent length 
or challenging deliverability of longer stents [5]. However, 
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the strategy of using overlapping stents can result in stent 
misplacement as well as increased risk of restenosis [5]. 
The newer-generation drug-eluting stents (DES) are de-
signed with reduced strut thickness and have been shown 
to be efficacious in treating very long coronary lesions 
[6, 7]. BioMime Morph (Meril Life Sciences Pvt. Ltd., Vapi, 
India) is a  long-tapered sirolimus-eluting stent (SES) sys-
tem designed for the treatment of very long coronary 
lesions including PCI of chronic total occlusions [6]. This 
long-tapered stent has been demonstrated to be associ-
ated with good procedural and 1-year clinical outcomes in 
complex patients with long and diffuse lesions [8].
Aim
The aim of our study was to assess clinical aspects, 
efficacy, and short-term follow-up safety of the novel 
long DES with tapered structure, tailored to fit the coro-
nary anatomy in patients with long coronary atheroscle-
rotic lesions. 
Material and methods
In this prospective clinical cohort study, we included 
32 consecutive patients admitted to the Department of 
Interventional Cardiology, Jagiellonian University College 
of Medicine and the John Paul II Hospital, Krakow, Poland 
between May 2016 and July 2017, who underwent PCI 
and in whom implantation of a  long, tapered DES was 
performed due to the presence of coronary lesions longer 
than 35 mm. BioMime Morph is an open-cell cobalt-chro-
mium sirolimus-eluting stent with closed cells on its ta-
pered end and was implanted in all patients who quali-
fied for inclusion in the study. The PCI procedures were 
Risk factors Value
Male sex 22 (69%)
Age, mean ± SD [years] 68.0 ±8.0
BMI, mean ± SD [kg/m2] 29.6 ±4.1
Medical history:
Arterial hypertension 30 (93.8%)
Systolic blood pressure, mean ± SD [mm Hg] 131 ±15
Diabetes 11 (34.4%)
Impaired glucose tolerance 4 (12.5%)
Dyslipidemia 28 (87.5%)
Prior PCI 14 (45.2%)
Prior CABG 2 (6.3%)
Prior myocardial infarction 14 (43.8%)
Indication for invasive coronary angiography:
Stable coronary artery disease 27 (84.4%)
Non-ST elevation myocardial infarction 3 (9.4%)
ST elevation myocardial infarction 1 (3.1%)
Unstable coronary artery disease 1 (3.1%)
Artery treated:
Left anterior descending 22 (68.8%)
Left circumflex 4 (12.5%)
Right coronary artery 6 (18.8%)
Bifurcation lesions 13 (40.6%)
MEDINA (0,1,1) 3 (9.4%)
MEDINA (1,0,1) 1 (3.1%)
MEDINA (1,1,0) 5 (15.6%)
MEDINA (1,1,1) 4 (12.5%)
Risk factors Value
Implanted stent length:
40 mm 10 (31.3%)
50 mm 13 (40.6%)
60 mm 9 (28.1%)
Implanted stent diameter:
2.75–2.25 mm 6 (18.8%)
3.0–2.5 mm 18 (56.3%)
3.5–3.0 mm 7 (21.9)
4.0–3.5 mm 1 (3.1%)
Procedure information:
NC balloon pre-dilatation 8 (25.0%)
Stiff guiding wire used 11 (34.4%)
“Buddy-wire” technique 3 (9.4%)
GuideLiner microcatheter use 4 (12.5%)
Additional stent needed 18 (56.3%)
Dissection present 8 (25.0%)
Dissection proximal to first stent 3 (9.4%)
Dissection distal to first stent 5 (15.6%)
Stent length too short 10 (31.3%)
Post-dilatation NC balloon use 22 (68.8%)
IVUS used 2 (6.3%)
Final TIMI 3 flow 32 (100.0%)
Contrast medium, median (IQR) [ml] 260 (200–370)
Radiation dose, median (IQR) [mGy] 1597 (761–2941)
Table I. Clinical characteristics of patients and procedures
BMI – body mass index, SD – standard deviation, D
max
 – maximal diameter measured in QCA, PCI – percutaneous coronary intervention, CABG – coronary artery 
bypass grafting, IQR – interquartile range. 
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performed according to current practice guidelines [4]. 
All patients provided written informed consent prior to 
the procedure. Interventional and pharmacological strat-
egies were left to the discretion of the operators. Dis-
tal-maximal and proximal-maximal diameter (D
max
) were 
calculated via quantitative coronary analysis (QCA) as di-
ameters of the vessel on the proximal and distal edge of 
the baseline lesion, respectively. Optimal PCI result was 
defined as full lesion coverage without coronary artery 
dissection and with proper apposition of the stent (less 
than 20% residual stenosis) in two perpendicular angio-
graphic projections. The clinical outcomes were assessed 
at 3-month, 6-month, and 12-month follow-ups.
At the 12-month observation, the following end-
points were assessed: death, myocardial infarction, tar-
get lesion revascularization (TLR), target vessel revascu-
larization (TVR), and major cerebrovascular event and/or 
major bleeding, adjudicated by independent researchers 
blinded to patient characteristics. Major bleeding was 
defined as bleeding with a need for hospitalization and/
or was fatal to the patient. All study procedures were per-
formed according to local bioethics committee guidance 
as well as the Helsinki Declaration.
Statistical analysis
We expressed continuous variables as mean with 
standard deviation or median with interquartile range 
for non-normal distributions. Discrete variables were pre-
sented as percentages. All analyses were performed in 
SPSS version 24 software (IBM).
Results
Patient characteristics
The study population consisted of 32 patients pre-
senting with typical CAD risk factor profiles, with a high 
percentage of diabetic or impaired glucose tolerance pa-
tients, positive history of myocardial infarction (MI) or 
PCI, and suboptimal treatment of dyslipidemia. 68.8% of 
the patients were male, with a mean age of 68 ±8 years. 
Most procedures were performed in stable coronary ar-
tery disease (SCAD), with 5 procedures performed in 
acute coronary syndromes (ACS). 
Procedure
In most cases, the target lesion was located in the left 
anterior descending artery (68.75%). About 60.0% of the 
procedures were performed using a transradial approach. 
The long-tapered BioMime Morph DES was successfully 
implanted in all 32 patients. Stents with a  diameter of 
3.0–2.5 mm (proximal to distal) were the most frequently 
used. We observed a need for deployment of an additional 
stent in 56% of the procedures (31% proximal and 25% 
distal to the implanted stent), in 25% of cases due to prox-
imal (15.6%) or distal (9.4%) dissection, or due to insuffi-
cient stent length in 31% of cases. Mean lesion length was 
48 mm, with a range of 35 to over 70 mm. Stent to base-
line minimal artery diameter ratio at the distal edge of le-
sion was 1.26 ±0.27, and was similar in groups with single 
stent treatment (1.30 ±0.29) and in patients who need-
ed additional stent implantation (1.24 ±0.26; p = 0.60 for 
t-test). Mean deployed to nominal stent diameter ratio at 
the distal edge was 0.90 ±0.13. A GuideLiner catheter was 
used in 12.5% of procedures, while the buddy-wire tech-
nique was used in 9.4% of cases. Bifurcation lesions were 
treated in 40.6% of cases, with predominant anatomy in 
MEDINA classification 1,1,0. No major side branch, defined 
as greater than 1 mm diameter, was lost. A transradial ap-
proach was used in 60% of the PCI procedures. The long-ta-
pered BioMime Morph drug-eluting stent (40–60 mm) was 
successfully implanted in all patients. Detailed character-
istics of patients and procedures are presented in Table I. 
Stent implantation images and the QCA analysis prior 
to and post-stent implantation are presented in Table II 
and in Figures 1 and 2.
Clinical follow-up
During the 3-month follow-up period, 1 (3.1%) patient 
was readmitted due to the reoccurrence of symptoms, in 
whom angiographic progression proximally to the previ-
ously deployed stent was revealed. The patient required 
target lesion revascularization (TLR) and no other major 
Table II. QCA analysis of coronary lesions
QCA analysis Value
Prior to angioplasty:
MLD prior to PCI, mean (SD) [mm] 0.68 (0.25)
Percent diameter stenosis, mean (SD) [%] 78.0 (13.6)
Lesion length, median (min.–max.) [mm] 50.93 (38.4–80.1)
Reference diameter 2.65 (0.34)
D
max
 proximal, mean (SD) [mm] 2.97 (0.30)
D
max
 distal, mean (SD) [mm] 2.16 (0.49)
After angioplasty:
MLD after PCI, mean (SD) [mm] 2.37 (0.45)
Residual stenosis after PCI [%] 9.1 (9.9)
D
max
 proximal, mean (SD) [mm] 3.13 (0.38)
D
max
 distal, mean (SD) [mm] 2.34 (0.46)
Proximal stent to vessel lumen diameter 
ratio, mean (SD)
0.99 (0.07)
Distal stent to vessel lumen diameter ratio, 
mean (SD) 
1.14 (0.18)
Lesion length to stent length ratio, mean (SD) 1.08 (0.19)
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adverse cardiac events (MACE) were observed. During 
the 6-month follow-up period no MACE were observed, 
although 1 patient was hospitalized for minor lower gas-
trointestinal bleeding. Data on 12-month follow-up were 
obtained from 30 patients. The TVR was observed in 
1 (3.3%) patient in the setting of stable CAD and another 
patient (3.3%) experienced ACS with non-target vessel 
as the culprit lesion. One patient died 8 months after PCI 
due to multi-organ-failure (MOF) with no evidence of ACS 
as the primary cause.
Discussion
The new-generation DES have become a  routine 
choice in the treatment of CAD. In current guidelines, full 
lesion coverage is the preferred PCI strategy [4]. Com-
plete revascularization in this setting often requires us-
ing multiple stents in a  single vessel, which is a  direct 
consequence of the maximum stent lengths currently 
available. There is still a lack of data about the treatment 
of long diffuse coronary lesions using the single or multi-
ple stent strategies. 
Many researchers have investigated the problem 
of stented segment length, demonstrating that longer 
stent lengths are associated with a significantly higher 
risk of stent thrombosis and major coronary events [5–8]. 
Since the length of the segment requiring PCI remains 
a non-addressable issue, we tried to assess the impact 
of overlap reduction. It has been shown that stent over-
Figure 1. Long-tapered stent implantation (40–60 mm)
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Figure 2. Quantitative coronary analysis (QCA) of lesion before (A) and after PCI (B)
A B
lap may be associated with impaired endothelialization. 
Increased strut density imposes a  greater risk of side 
branch compromise, and additionally increases the risk 
of local stent fractures and arterial wall injury [9]. Giv-
en these factors, stent overlap compared with no over-
lap is associated with impaired clinical and angiographic 
outcomes during long-term follow-up [8, 10]. Moreover, 
standard new-generation DES hold their diameter with 
the stent length, which in cases of very long lesions may 
be a  cause of stent size mismatch with the distal cor-
onary lumen [11]. Using a  long single-tapered DES ad-
dresses these aforementioned issues, theoretically giving 
a reduced risk of complications. 
In our experience, device implantation appears to be 
efficacious independently of clinical presentation [12, 
13]. In our case series, an all comers population was 
treated. We successfully deployed the stent in 100% of 
the procedures. However, long lesion angioplasty has 
a  significant learning curve, especially when diffused 
atherosclerosis is present, and operator experience is of 
tremendous significance. 
We observed one TVR in the 3-month follow-up, and 
another one on 12-month follow-up, with one death (due 
to MOF) and no major bleeding. Furthermore, no other 
MACE were seen at 12 months, which in our opinion is 
an encouraging result.
One should note a need for additional stent implan-
tation in 56% of the procedures, in 25% of cases due to 
dissection presence (both proximal or distal) and in the 
remaining 31% of cases due to insufficient length of the 
first implanted stent. The latter was probably due to a ten-
dency for the operator to underestimate the lesion length 
or occurrence of unanticipated problems with long-stent 
insertion into the distal part of the vessel. Given the good 
deliverability of the device, even if in some cases “bud-
dy wire” technique or extension catheter was needed, 
it might suggest the use of longer, even 60 mm tapered 
stents, to avoid overlap in the future. In addition, the ex-
pansion ratio of distal artery diameter, over 1.2 times com-
pared to baseline, was associated with a low percentage 
of distal dissection, which was present in 15% of patients. 
The notably low radial access rate, only in 60% of cas-
es, might have been due to the anticipated complexity 
of procedure, caused by anatomy and length of lesions. 
However, there was a 100% success rate of stent delivery 
in both femoral and radial access groups, irrespective of 
clinical setting. We used the GuideLiner catheter in only 
12.5% of cases, while the buddy-wire technique was 
used in 9.4% of cases. In our opinion, these observations 
demonstrate acceptable deliverability of the device in an 
all comers population. Obviously, proper preparation of 
the lesion with high pressure inflations is crucial to facil-
itate stent delivery and decrease the need for additional 
technique application (e.g. “buddy wire” technique, ex-
tension microcatheter). 
Contrast medium usage in our case series was similar 
to those in recently emerging clinical studies with long 
stents [14, 15]. We hypothesize that a  lower number of 
implanted stents should result in lower contrast medi-
um and radiation use. However, there is still a  lack of 
published data involving a direct comparison of multiple 
stenting versus the long single-stent strategy in terms of 
contrast expenditure or radiation exposure. 
Study limitations
The present study included a relatively small, all-com-
ers patient population and requires a larger cohort study 
for replication of these results. A second limitation is the 
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lack of a control group to compare the use of contrast 
medium and radiation exposure.
Conclusions
The long sirolimus-eluting stent with tapered struc-
ture was characterized by good deliverability in long 
coronary lesions, although in some cases “buddy wire” 
or extension microcatheter use was necessary. Previous 
lesion preparation even with a  non-compliant balloon 
is important for successful stent introduction. Operator 
experience in complex PCI plays an important role. Fol-
low-up at 3, 6, and 12 months showed no significant ma-
jor adverse cardiovascular events associated with the de-
vice. Further investigational clinical trials are needed to 
compare multiple vs. single-stent strategies in patients 
with long coronary lesions.
Conflict of interest
The authors declare no conflict of interest.
References 
1. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines 
on cardiovascular disease prevention in clinical practice. Eur 
Heart J 2016; 37: 2315-81. 
2. Podolec J, Kopec G, Niewiara L, et al. Chemokine RANTES is 
increased at early stages of coronary artery disease. J Physiol 
Pharmacol 2016; 67: 321-8.
3. Podolec J, Niewiara L, Skiba D, et al. Higher levels of circulating 
naïve CD8 + CD45RA + cells are associated with lower extent of 
coronary atherosclerosis and vascular dysfunction. Int J Cardiol 
2018; 259: 26-30. 
4. Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines 
on myocardial revascularization. Eur J Cardiothoracic Surg 2014; 
46: 517-92.
5. Aoki J, Ong ATL, Rodriguez Granillo GA, et al. “Full metal jacket” 
(stented length > or =64 mm) using drug-eluting stents for de 
novo coronary artery lesions. Am Heart J 2005; 150: 994-9. 
6. Ruchin PE, Trabattoni D, Fabbiocchi F, et al. Use of multiple over-
lapping sirolimus-eluting stents for treatment of long coronary 
artery lesions: results from a single-center registry in 318 con-
secutive patients. Int J Cardiol 2009; 134: 231-7. 
7. Caputo RP, Goel A, Pencina M, et al. Impact of drug eluting stent 
length on outcomes of percutaneous coronary intervention 
(from the EVENT Registry). Am J Cardiol 2012; 110: 350-5. 
8. Räber L, Jüni P, Löffel L, et al. Impact of stent overlap on angio-
graphic and long-term clinical outcome in patients undergoing 
drug-eluting stent implantation. J Am Coll Cardiol 2010; 55: 
1178-88. 
9. Lim SY, Jeong MH, Hong SJ, et al. Inflammation and delayed en-
dothelization with overlapping drug-eluting stents in a porcine 
model of in-stent restenosis. Circ J 2008; 72: 463-8.
10. Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolim-
us-eluting stent implantation for de novo coronary lesions. Am 
J Cardiol 2004; 93: 826-9.
11. Timmins LH, Meyer CA, Moreno MR, Moore JE. Mechanical mod-
eling of stents deployed in tapered arteries. Ann Biomed Eng 
2008; 36: 2042-50. 
12. Podolec J, Niewiara Ł, Baran J, et al. First in Poland, unique 60-
mm long single drug eluting tapered stent implantation in a pa-
tient with unstable angina. Kardiol Pol 2017; 75: 78. 
13. Podolec J, Baran J, Niewiara Ł, et al. Intravascular ultrasonogra-
phy guided 60-mm long drug-eluting tapered stent implantation 
in a long calcified lesion in a patient with stable coronary artery 
disease. Adv Interv Cardiol 2017; 13: 88-9. 
14. Valero E, Consuegra-Sánchez L, Miñana G, et al. Initial experi-
ence with the novel BioMime 60 mm-long sirolimus-eluting ta-
pered stent system in long coronary lesions. Eurointervention 
2018; 13: 1591-4.
15. Premchand RK, Kumar YS. A report of successful procedural, clin-
ical, and angiographic outcomes with a tapered stent of a pa-
tient in naturally tapered coronary vessel. J Clin Diagn Res 2017; 
11: OD06-7. 
